Patents by Inventor Jagath Reddy Junutula

Jagath Reddy Junutula has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
    Publication number: 20180000962
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: May 10, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, JR., Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR HEMATOPOIETIC ORIGIN
    Publication number: 20170362318
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: January 13, 2017
    Publication date: December 21, 2017
    Inventors: Craig Crowley, Frederic J. De Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Junutula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
  • Humanized anti-CD79b antibodies and immunoconjugates and methods of use
    Patent number: 9845355
    Abstract: The present invention is directed to anti-CD79b antibodies with specific hypervariable region sequences in the heavy and light chain variable domains as enumerated in the SEQ ID NOs described herein.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: December 19, 2017
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • IMMUNOCONJUGATES COMPRISING ANTI-HER2 ANTIBODIES AND PYRROLOBENZODIAZEPINES
    Publication number: 20170274092
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 28, 2017
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20170174782
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 18, 2016
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170166635
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p ??(I) where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 15, 2017
    Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20170058032
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 2, 2017
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 9518118
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20160096893
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 11, 2015
    Publication date: April 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20150314016
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: June 9, 2015
    Publication date: November 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150158952
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 11, 2015
    Applicant: GENENTECH, INC.
    Inventors: Weiguang MAO, Jagath Reddy JUNUTULA, Paul POLAKIS
  • Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
    Patent number: 8937161
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: January 20, 2015
    Assignee: Genentech, Inc.
    Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
  • CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
    Publication number: 20150017188
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: January 10, 2014
    Publication date: January 15, 2015
    Applicant: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, JR., Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20140335107
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 19, 2014
    Publication date: November 13, 2014
    Applicant: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
  • Anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 8722857
    Abstract: The present invention is directed to cysteine-engineered anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: May 13, 2014
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
  • Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
    Publication number: 20140099260
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: August 22, 2013
    Publication date: April 10, 2014
    Applicant: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 8691531
    Abstract: The present invention is directed to compositions of matter comprising nucleic acids encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 207 or 208, encoding an anti-CD79b antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 207 and the light chain variable domain sequence of SEQ ID NO: 208, or encoding an anti-CD79b antibody having : (i) a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 194, a HVR-L2 having the sequence of SEQ ID NO: 195, and a HVR-L3 having the sequence of SEQ ID NO: 196 and (ii) a variable light chain comprising a HVR-H1 having the sequence of SEQ ID NO: 202, a HVR-H2 having the sequence of SEQ ID NO: 203, and a HVR-H3 having the sequence of SEQ ID NO: 204, and vectors and host cells thereof.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: April 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 8545850
    Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: October 1, 2013
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Cysteine engineered antibodies and conjugates
    Patent number: 8309300
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: November 13, 2012
    Assignee: Genentech, Inc.
    Inventors: Jagath Reddy Junutula, Henry Lowman
  • Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
    Publication number: 20120148600
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 28, 2011
    Publication date: June 14, 2012
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng